REGN

Regeneron Pharmaceuticals
D

REGN

588.31
USD
-8.34
(-1.40%)
مفتوح الان
حجم التداول
12,211
الربح لكل سهم
35
العائد الربحي
0.29
P/E
15
حجم السوق
63,517,181,540
أصول ذات صلة
AMGN
AMGN
-0.70
(-0.26%)
271.37 USD
BIIB
BIIB
-0.760
(-0.60%)
125.530 USD
BMY
BMY
-0.150
(-0.32%)
46.860 USD
GILD
GILD
0.630
(0.59%)
107.350 USD
INCY
INCY
-0.060
(-0.09%)
64.440 USD
MRK
MRK
-0.225
(-0.29%)
77.630 USD
PFE
PFE
0.060
(0.26%)
23.290 USD
VRTX
VRTX
1.29
(0.30%)
435.61 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).